DDInter1042 DDInter1635
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salmeterol {u} (Compound) resembles {v} (Compound) Hexoprenaline
Salmeterol {u} (Compound) treats {v} (Disease) asthma
Salmeterol {u} (Compound) binds {v} (Gene) ADRB2
Salmeterol {u} (Compound) upregulates {v} (Gene) EDEM1
Salmeterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Salmeterol {u} (Compound) downregulates {v} (Gene) CDC20
Salmeterol {u} (Compound) causes {v} (Side Effect) Chronic obstructive pulmonary disease
Salmeterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrocortisone
Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Salmeterol (Compound) resembles Hexoprenaline (Compound)
Salmeterol (Compound) treats asthma (Disease)
Salmeterol (Compound) binds ADRB2 (Gene)
Salmeterol (Compound) upregulates EDEM1 (Gene)
Salmeterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Salmeterol (Compound) downregulates CDC20 (Gene)
Salmeterol (Compound) causes Chronic obstructive pulmonary disease (Side Effect)
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone